Trial Profile
Expanded Access for ACE-011
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 21 Jul 2020
Price :
$35
*
At a glance
- Drugs Sotatercept (Primary)
- Indications Myelodysplastic syndromes
- Focus Expanded access; Therapeutic Use
- Sponsors Celgene Corporation
- 16 Jul 2020 Status changed from recruiting to completed.
- 05 Nov 2018 New trial record